Skip to main content
SpringerLink
Log in

L’hormonothérapie néo-adjuvante en janvier 2005

  • Conference paper
Cancer du sein

  • 241 Accesses

Conclusion

L’hormonothérapie néo-adjuvante voit aujourd’hui ses indications se développer. Chez les personnes âgées, elle fait maintenant partie de la stratégie de référence, précédant le traitement loco-régional. Elle permet, en effet, une fois sur deux environ, d’éviter une mastectomie, qui peut être mal acceptée par certaines patientes qui perçoivent cette mutilation comme la déchéance débutante et irrémédiable de la sénescence. Une anti-aromatase doit alors être proposée. Des évaluations cliniques très régulières permettront de poursuivre le traitement jusqu’à l’obtention d’une réduction tumorale suffisante pour permettre un traitement loco-régional, toujours nécessaire.

Chez les femmes plus jeunes, l’hormonothérapie néo-adjuvante a très certainement sa place, qui demeure cependant actuellement mal définie, compte tenu des indications très larges de la chimiothérapie (néo-) adjuvante. Son utilisation dans des études prospectives permet de mieux appréhender les facteurs prédictifs de la réponse au traitement, tout particulièrement dans le cadre d’analyses génomiques déjà en cours pour la chimiothérapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Chauvergne J, Durand M, Hoerni B et al. (1979) La chimiothérapie d’induction dans les cancers du sein à haut risque. Résultats d’une étude thérapeutique prospective. Bull Cancer (Paris), 66: 9–16

    PubMed  CAS  Google Scholar 

  2. Alonzo-Munoz A, Perez Manga G, Moreno Esteban B et al. (1980) treatment of advanced breast cancer with tamoxifen. Med Clin (Barc) 75(3): 93–7

    Google Scholar 

  3. Veronesi A, Frustaci S, Tirelli U et al. (1981) Tamoxifen therapy in postmenopausal advanced breast cance: efficacy at the primary tumor site in 46 evaluable patients. Tumori 67(3): 235–8

    PubMed  CAS  Google Scholar 

  4. Preece PE, Wood RA, Mackie CR et al. (1982) Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J 284: 969–70

    Google Scholar 

  5. Helleberg A, Lundgren B, Norin T et al. (1982) Treatment of early localised breast cancer in elderly patients by tamoxifen. Br J Radiol 55: 511–5

    Article  PubMed  CAS  Google Scholar 

  6. Bradbeer JW, Kyngdon J (1983) Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 9: 31–4

    PubMed  CAS  Google Scholar 

  7. Robertson JFR, Ellis IO, Elston CW et al. (1992) Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients. Eur J Cancer 28A: 908–10

    Article  PubMed  CAS  Google Scholar 

  8. Gazet JC, Ford HT, Bland JM et al. (1988) prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. The Lancet I: 679–81

    Article  Google Scholar 

  9. Gazet JC, Ford HT, Coombes RT et al. (1994) Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20: 207–14

    PubMed  CAS  Google Scholar 

  10. Mustacchi G, Milani S, Pluchinotta A et al. (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer. Anticancer Res 14: 2197–200

    PubMed  CAS  Google Scholar 

  11. Bates T, Riley DL, Houghton J et al. (1991) Breast cancer in elderly women: a cancer Research Campain trial comparing treatment with tamoxifen and optimal surgery with tamoxifen. Br J Surg 78: 591–5

    PubMed  CAS  Google Scholar 

  12. Williams MR, Gilson D, Marsh L et al. (1988) The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg oncol 14: 235–40

    PubMed  CAS  Google Scholar 

  13. Fennessy M, Bates T, Mac Rae K et al. (2004) Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surgery 91: 699–704

    Article  CAS  Google Scholar 

  14. Mustacchi G, Ceccherini R, Milani S et al. (2003) Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long term results of the phase III randomised controlled multicenter GRETA trial. Ann Oncol 14: 414–20

    Article  PubMed  CAS  Google Scholar 

  15. Anderson ED, Forrest AP, Levack PA et al. (1989) Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J cancer 60(2): 223–6

    PubMed  CAS  Google Scholar 

  16. Cameron DA, Jack W, Forouhi P et al. (2002) Oestrogen receptor directed primary systemic therapy: a randomised trial compared with conventional therapy in operable breast cancer. 25th Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 76: S52 (abs 157)

    Google Scholar 

  17. Gazet JC, Ford HT, Gray R et al.. (2001) Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 12: 685–91

    Article  PubMed  CAS  Google Scholar 

  18. Gazet JC, Ford HT, Coombes RC et al. (1991) Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br J Cancer 63: 279–82

    PubMed  CAS  Google Scholar 

  19. Wilsher PC, Robertson JF, Chan SY et al. (1997) Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 33: 45–9

    Article  Google Scholar 

  20. Tan SM, Cheung KL, Wilsher PC et al. (2001) Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 37: 2331–8

    Article  PubMed  CAS  Google Scholar 

  21. Semiglazov VF, Invanov VG, Semiglazov VV et al. (2004) Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER-positive breast cancer patients. 27th Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 88: S106 (abs 2090)

    Google Scholar 

  22. Von Minckwitz G, Costa S, Raab G et al. (2001) Dose dense doxorubicin, docetaxel and GCSF support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast. J Clin Oncol 19: 3506–515

    Google Scholar 

  23. Cocconi G, di Blasio B, Bisagni G et al. (1990) Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomised study. Am J Clin Oncol 13(3): 226–32

    PubMed  CAS  Google Scholar 

  24. Wolf CJ, Raab G, Eiermann W, Grammatikakis I (2004) An open label, randomized phase II trial of primary systemic therapy with exemestane (EXE 25 mg/d) plus epirubicin (EPI, 20 vs 30 mg/m2 q1w × 8–12) in breast cancer: An interim analysis of the German Neoadjuvant Aromasin Initiative (GENARI-3). American Society of Clinical Oncology 40th meeting. New Orleans, Louisana June 5–8, abs 826

    Google Scholar 

  25. Tortoriello A, Pacelli R, Procaccini E et al. (2001) Letrozole + pamidronate ± docetaxel + radiotherapy in the treatment of bone metastases by breast cancer. Preliminary data of a phase II study. American Society of Clinical Oncology 37th meeting. San Francisco, California May 12–15. Abs 1833

    Google Scholar 

  26. Lichtenegger W, Hackl W, Huettner C et al. (2001) Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer. American Society of Clinical Oncology 37th meeting. San Francisco, California May 12–15. Abs 1832

    Google Scholar 

  27. Perez Manga G, Garcia Bueno JM, Palombo H et al. (2004) A phase II study of vinorelbine (VNR) and letrozole (LTZ) in aged women with metastatic breast cancer (MBC). American Society of Clinical Oncology 40th meeting. New Orleans, Louisana June 5–8. Abs 756

    Google Scholar 

  28. Gennatas CS, Mouratidou DC, Tsavaris NV et al. (2002) Randomized study of docetaxel and mitoxantrone, versus docetaxel, mitoxantrone and letrozole as first-line therapy in advanced breast cancer (Hellenic Group of Oncology, HELLGO). 27th European Society for Medical Oncology. Nice, France 18–22 octobre 2002. Ann Oncol 13suppl 5: 52 (abs 186P)

    Google Scholar 

  29. Dirix LY, Ignacio J, Nag S et al. (2003) Final results from an open-label, multicenter, controlled study of exemestane +/− celecoxib in postmenopausal women with advanced breast cancer (ABC) progressed on tamoxifen (T). Proc Am Soc Clin Oncol 22: 20 (abstr 77)

    Google Scholar 

  30. Chow LWC, Toi M, Takebayashi Y, Sasano H (2003) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: second report. 26th Annual San Antonio. Breast Cancer Symposium. December 3–6, 2003. Abs 428

    Google Scholar 

  31. Dixon JM, Love CDB, Bellamy COC et al. (2001) Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66: 191–9

    Article  PubMed  CAS  Google Scholar 

  32. Dixon JM, Anderson TJ, Miller WR (2002) Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38: 2214–21

    Article  PubMed  CAS  Google Scholar 

  33. Tubiana-Hulin M, Spyratos F (2004) Response to neo-adjuvant exemestane in post-menopausal breast cancer patients: Correlation with biological factors measured by real-time quantitative RT-PCR (QRT-PCR). American Society of Clinical Oncology 40th meeting. New Orleans, Louisana June 5–8. abs 538

    Google Scholar 

  34. Harper-Wynne CL, Sacks NPM, Shenton K et al. (2002) Comparison of the systemic and intratumoral effects of Tamoxifen end the aromatase inhibitor Vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20: 1026–35

    Article  PubMed  CAS  Google Scholar 

  35. Eiermann W, Paepke S, Appfelstaedt J et al. (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12(11): 1527–32

    Article  PubMed  CAS  Google Scholar 

  36. Smith I, Dowsett M (2003) Comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment for oestrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. 26th Annual San Antonio Breast Cancer Symposium. December 3–6, 2003. Br Cancer Res Treat 82(suppl1): S6. Abs 1

    Google Scholar 

  37. Cataliotti L, Buzdar A, Noguchi S, Bines J (2004) Efficacy of preoperative Arimidex (anastrozole) compared with Tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. 4th European Breast Cancer Conference. Hambourg, 16–20 mars 2004. Eur J Cancer supplements 2(3): 69

    Article  Google Scholar 

  38. Semiglazov VF, Semiglazov VV, Ivanov VG et al. (2003) Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4N1-2MO). 26th Annual San Antonio Breast Cancer Symposium. December 3–6, 2003. Br Cancer Res Treat 82(suppl1): S22. Abs 111

    Google Scholar 

  39. Smith I, Cataliotti L (2004) Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the PROACT and the IMPACT trials. 4th European Breast Cancer Conference. Hambourg 16–20 Mars 2004. Eur J Cancer supplements 2(3): abs 2

    Google Scholar 

  40. Kuerer HM, Newman LA, Smith TL et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node respponse to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460–9

    PubMed  CAS  Google Scholar 

  41. Mauriac L, Debled M, Durand M et al. (2002) Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 13: 293–8

    Article  PubMed  CAS  Google Scholar 

  42. Trufflandier N, Mauriac L, Durand M et al. (2003) Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women: a 118-month median follow-up. 4th European Breast Cancer Conference. Hambourg 16–20 Mars 2004. Eur J Cancer Supplements 2(3): 73 (abs 57)

    Article  Google Scholar 

  43. Soubeyran I, Quenel N, Coindre JM et al. (1996) pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 1974: 1120–5

    Google Scholar 

  44. Ellis MJ, Coop A, Singh B et al. (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63(19): 6523–31

    PubMed  CAS  Google Scholar 

  45. Anderson TJ, Dixon MJ, Murray J et al. (2004) Early changes in tumour Ki67 expression differentiate fot pathological (but not clinical) response in brest cancers treated neo-adjuvantly with letrozole. 27th Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 88: S50 (abs 1027)

    Article  Google Scholar 

  46. Ellis MJ, Coop A, Singh B et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19: 3808–16

    PubMed  CAS  Google Scholar 

  47. Dixon JM, Anderson TJ, Miller WR (2002) Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38: 2214–21

    Article  PubMed  CAS  Google Scholar 

  48. Renshaw L, Murray J, Young O et al. (2004) Is there an optimal duration of neoadjuvant letrozole therapy? 27th Annual San Antonio. Breast Cancer Symposium. December 8–11, 2003. Br Cancer Res Treat; 88(suppl. 1): S36 (abs 405)

    Google Scholar 

  49. Cameron DA, Anderson EDC, Levack P et al. (1997) Primary systemic therapy for operable breast cancer-10 year survival data after chemotherapy and hormone therapy. Br J Cancer 76: 1099–105

    PubMed  CAS  Google Scholar 

  50. Horobin JM, Preece PE, Dewar JA et al. (1991) Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78: 213–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine, Institut Bergonié, Centre régional de lutte contre le cancer, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    M. Debled & L. Mauriac

  2. Service d’anapathologie, Institut Bergonié, Centre régional de lutte contre le cancer, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    G. MacGrogan

  3. Service de chirurgie, Institut Bergonié, Centre régional de lutte contre le cancer, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    C. Tunon de Lara

Authors
  1. M. Debled
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Mauriac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. MacGrogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Tunon de Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Debled, M., Mauriac, L., MacGrogan, G., Tunon de Lara, C. (2006). L’hormonothérapie néo-adjuvante en janvier 2005. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_17

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation